Is Coenzyme Q10 Migraine Meta-Analysis safe?

Updated May 2026

Quick Answer

Coenzyme Q10 Migraine Meta-Analysis has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: 1 2 3 4 5 Migraine is a chronic, disabling neurovascular disorder characterized by recurrent episodes of moderate-to-severe headache, typically unilateral and pulsating in quality, and frequently associated with nausea, vomiting, photophobia, and phonophobia.

Key Takeaways

  • 011 2 3 4 5 Migraine is a chronic, disabling neurovascular disorder characterized by recurrent episodes of moderate-to-severe headache, typically unilateral and pulsating in quality, and frequently associated with nausea, vomiting, photophobia, and phonophobia. [Santangelo Domenico (2026)]
  • 02These processes result in peripheral and central sensitization of nociceptive pathways, thereby amplifying pain perception and contributing to migraine chronicization []. [Santangelo Domenico (2026)]
  • 036 7 6 8 9 10 11 A growing body of evidence indicates that patients with migraine show impaired energy metabolism and reduced metabolic flexibility []. [Santangelo Domenico (2026)]
  • 04In approximately one-third of patients, migraine attacks are preceded or accompanied by transient focal neurological symptoms, known as aura, which most frequently manifests as visual disturbances but may also involve sensory, language, or motor symptoms []. [Santangelo Domenico (2026)]
The current Migaku evidence database contains 2 reusable source documents for Coenzyme Q10 Migraine Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - 1 2 3 4 5 Migraine is a chronic, disabling neurovascular disorder characterized by recurrent episodes of moderate-to-severe headache, typically unilateral and pulsating in quality, and frequently associated with nausea, vomiting, photophobia, and phonophobia. [Santangelo Domenico (2026); evidence level 3] - These processes result in peripheral and central sensitization of nociceptive pathways, thereby amplifying pain perception and contributing to migraine chronicization []. [Santangelo Domenico (2026); evidence level 3] - 6 7 6 8 9 10 11 A growing body of evidence indicates that patients with migraine show impaired energy metabolism and reduced metabolic flexibility []. [Santangelo Domenico (2026); evidence level 3] - In approximately one-third of patients, migraine attacks are preceded or accompanied by transient focal neurological symptoms, known as aura, which most frequently manifests as visual disturbances but may also involve sensory, language, or motor symptoms []. [Santangelo Domenico (2026); evidence level 3] - A growing body of evidence points to a significant link between migraine and disruptions in brain energy metabolism (). [Sun Wen-xiu (2025); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms
  2. Energy metabolism disorders in migraine: triggers, pathways, and therapeutic repurposing